Form 4: Amgen SVP Khosla Reports Routine Stock Transaction
Insider Transaction Report
Amgen's SVP of Business Development, Rachna Khosla, reported a disposition of 226 common shares for tax withholding purposes related to equity vesting.
Summary
- Rachna Khosla, SVP, Business Development at Amgen Inc., reported a transaction involving Amgen common stock.
- On November 5, 2025, 226 shares of common stock were disposed of at a price of $296.7 per share.
- This disposition was coded as "F," indicating shares withheld for tax liability incident to the vesting of a security.
- Following this transaction, Khosla beneficially owns 7,972 shares of Amgen common stock directly.
- The reported shares include 93 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, credited on unvested RSUs and paid out in shares.
Sentiment
Score: 5
Explanation: Neutral. The transaction is a routine, non-discretionary event for tax withholding related to equity vesting, which is a common occurrence for executives.
Positives
- The transaction is a routine, non-discretionary event related to equity compensation, indicating continued employee retention and vesting of previously granted awards.
Negatives
- No specific negative implications are apparent from this routine tax-related disposition.
Future Outlook
NA
Industry Context
This is a standard insider transaction filing (Form 4) reporting a non-discretionary disposition of shares for tax purposes upon the vesting of equity awards. Such filings are common across all publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Amgen, where equity compensation is a significant component of executive remuneration.
Stakeholder Impact
- Shareholders: Minimal direct impact as it's a routine tax-related transaction, not a discretionary sale indicating a change in sentiment.
- Employees: Reflects the standard practice of equity compensation and vesting for executives.
Key Dates
| Date | Description |
|---|---|
| 11/05/2025 | Date of earliest transaction (disposition of common stock). |
| 11/05/2025 | Date the Form 4 was signed and filed. |
Keywords
Amgen, AMGN, Insider Transaction, Form 4, Stock Disposition, Tax Withholding, Equity Compensation, Rachna Khosla, SVP Business Development
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.